ME02059B - Protutijela protiv gm-csf i njihova upotreba - Google Patents
Protutijela protiv gm-csf i njihova upotrebaInfo
- Publication number
- ME02059B ME02059B MEP-2015-5A MEP515A ME02059B ME 02059 B ME02059 B ME 02059B ME P515 A MEP515 A ME P515A ME 02059 B ME02059 B ME 02059B
- Authority
- ME
- Montenegro
- Prior art keywords
- human
- functional fragment
- humanized antibody
- csf
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (22)
1. Izolirano ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, naznačeno time što ima antigenski vežuće područje specifično za ljudski GM-CSF i ima H-CDR1 slijed GFTFSSYWMN, H-CDR2 slijed GIENKRAGGATFYAASVKG, GIESKWAGGATYYAAGVKG, ili GIENKYAGGATYYAASVKG, H-CDR3 slijed GFGTDF, L-CDR1 slijed SGDSIGKKYAY, L-CDR2 slijed KKRPS i L-CDR3 slijed SAWGDKGM.
2. Ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, u skladu s patentnim zahtjevom 1 koje ima antigenski vežuće područje specifično za ljudski GM-CSF, naznačeno time što navedeno izolirano ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, može (i) najmanje 50% blokirati međudjelovanje između 0,5 µg/ml ljudskog GM-CSF s α lancem ljudskog GM-CSF receptora eksprimiranim na otprilike 2 × 105 stanica CHO-K1 u sljedećim uvjetima: (a) koncentracija α lanca navedenog ljudskog GM-CSF receptora eksprimiranog na navedenim stanicama CHO-K1 je slična koncentraciji α lanca ljudskog GM-CSF receptora eksprimiranog na otprilike 2 × 105 stanica CHO-GMRa#11 i (b) koncentracija navedenog izoliranog ljudskog ili humaniziranog protutijela, ili njegovog funkcionalnog fragmenta, je otprilike 5 µg/ml; i (ii) neutralizirati 0,25 ng/ml ljudskog GM-CSF u ispitivanju proiliferiranja TF-1 uz najmanje pet puta manju vrijednost IC50 nego referentno protutijelo BVD2-21C11 (BD Biosciences Pharmingen; kat. br. 554503) i/ili protutijelo MAB215 (R&D Systems; kat. br. MAB215).
3. Ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što ima varijabilni teški lanac kojeg se bira iz skupine koju čine (a) QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSG IENKRAGGATFYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR GFGTDFWGQGTLVTVSS, (b) QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSG IESKWAGGATYYAAGVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR GFGTDFWGQGTLVTVSS i (c) QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSG IENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR GFGTDFWGQGTLVTVSS.
4. Ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačeno time što ima varijabilni laki lanac kojeg se bira iz skupine koju čine (a) DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKK RPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTK LTVLGQ, (b) DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKK RPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTK LTVLGQ i (c) DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKK RPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTK LTVLGQ.
5. Ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačeno time što ima H-CDR3 slijed GFGTDF, H-CDR2 slijed GIENKYAGGATYYAASVKG, H-CDR1 slijed GFTFSSYWMN i L-CDR3 slijed SAWGDKGM, L-CDR2 slijed KKRPS i L-CDR1 slijed SGDSIGKKYAY.
6. Ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, u skladu s patentnim zahtjevom 5, naznačeno time što ima (a) varijabilni teški lanac sa slijedom QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSG IENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR GFGTDFWGQGTLVTVSS i (b) varijabilni laki lanac sa slijedom DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKK RPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTK LTVLGQ.
7. Ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačeno time što navedeni ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, ukriženo reagira sa štakorskim GM-CSF i/ili rezus GM-CSF.
8. Ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačeno time što navedeno protutijelo, ili njegov funkcionalni fragment, može neutralizirati ljudski GM-CSF u ispitivanju proiliferiranja TF-1 uz najmanje 10 puta manju vrijednost IC50 nego referentno protutijelo MAB215 (R&D Systems; kat. br. MAB215) i/ili BVD2-21C11 (BD Biosciences Pharmingen; kat. br. 554503).
9. Funkcionalni fragment protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je Fab ili scFV fragment protutijela.
10. Ljudsko ili humanizirano protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačeno time što je ljudski protutijelo.
11. Ljudsko ili humanizirano protutijelo u skladu s patentnim zahtjevom 10, naznačeno time što je IgG.
12. Nukleinskokiselinski slijed, naznačen time što kodira antigenski vežuće područje ljudskog ili humaniziranog protutijela, ili njegovog funkcionalnog fragmenta, u skladu s bilo kojim od patentnih zahtjeva 1 do 11.
13. Nukleinskokiselinski slijed u skladu s patentnim zahtjevom 12, naznačen time što ima (i) nukleotidni slijed kojeg se bira iz skupine koju čine (a) CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGC GGCAGCCTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTTCT TCTTATTGGATGAATTGGGTGCGCCAAGCCCCTGGGAAGGGTCTC GAGTGGGTGAGCGGTATTGAGAATAAGCGTGCTGGTGGTGCTACT TTTTATGCTGCTTCCGTTAAGGGTCGTTTTACCATTTCACGTGAT AATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCG GAAGATACGGCCGTGTATTATTGCGCGCGTGGTTTTGGTACTGAT TTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA, (b) CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGC GGCAGCCTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTTCT TCTTATTGGATGAATTGGGTGCGCCAAGCCCCTGGGAAGGGTCTC GAGTGGGTGAGCGGTATTGAGTCTAAGTGGGCTGGTGGTGCTACT TATTATGCTGCTGGTGTTAAGGGTCGTTTTACCATTTCACGTGAT AATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCG GAAGATACGGCCGTGTATTATTGCGCGCGTGGTTTTGGTACTGAT TTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA, (c) CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGC GGCAGCCTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTTCT TCTTATTGGATGAATTGGGTGCGCCAAGCCCCTGGGAAGGGTCTC GAGTGGGTGAGCGGTATTGAGAATAAGTATGCTGGTGGTGCTACT TATTATGCTGCTTCTGTTAAGGGTCGTTTTACCATTTCACGTGAT AATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCG GAAGATACGGCCGTGTATTATTGCGCGCGTGGTTTTGGTACTGAT TTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA i (d) CAGGTGCAGCTGGTCGAGTCTGGCGGCGGACTGGTGCAGCCTGGC GGCAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAGC AGCTACTGGATGAACTGGGTGAGGCAGGCCCCTGGCAAGGGCCTG GAGTGGGTGTCCGGCATCGAGAACAAGTATGCCGGCGGAGCCACC TACTACGCCGCCAGCGTGAAGGGCCGGTTCACCATCAGCCGGGAC AACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCC GAGGACACCGCCGTGTACTACTGTGCCAGGGGCTTCGGCACCGAT TTCTGGGGCCAGGGCACCCTGGTGACAGTCAGCTCA; ili (ii) nukleinskokiselinski slijed koji u vrlo striktnim uvjetima hibridizira s komplementarnim lancem slijeda iz (i)(a), (i)(b), (i)(c) ili (i)(d).
14. Nukleinskokiselinski slijed u skladu s patentnim zahtjevom 12, naznačen time što ima (i) nukleotidni slijed kojeg se bira iz skupine koju čine (a) GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGT CAGACCGCGCGTATCTCGTGTAGCGGCGATTCTATTGGTAAGAAG TATGCTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCTT GTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACT CAGGCGGAAGACGAAGCGGATTATTATTGCTCTGCTTGGGGTGAT AAGGGTATGGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGC CAG, (b) GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGT CAGACCGCGCGTATCTCGTGTAGCGGCGATTCTATTGGTAAGAAG TATGCTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCTT GTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACT CAGGCGGAAGACGAAGCGGATTATTATTGCTCTGCTTGGGGTGAT AAGGGTATGGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGC CAG, (c) GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGT CAGACCGCGCGTATCTCGTGTAGCGGCGATTCTATTGGTAAGAAG TATGCTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCTT GTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACT CAGGCGGAAGACGAAGCGGATTATTATTGCTCTGCTTGGGGTGAT AAGGGTATGGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGC CAG i (d) GACATCGAGCTGACCCAGCCCCCCAGCGTGTCTGTGGCCCCTGGC CAGACCGCCCGGATCAGCTGCTCCGGCGACAGCATCGGCAAGAAG TACGCCTACTGGTATCAGCAGAAGCCCGGCCAGGCCCCCGTGCTG GTGATCTACAAGAAGCGGCCCAGCGGCATCCCCGAGCGGTTCAGC GGCAGCAACAGCGGCAACACCGCCACCCTGACCATCAGCGGCACC CAGGCCGAGGACGAGGCCGACTACTACTGCTCCGCCTGGGGCGAC AAGGGCATGGTGTTTGGCGGCGGAACAAAGTTAACCGTGCTGGGG CAG; ili (ii) nukleinskokiselinski slijed koji u vrlo striktnim uvjetima hibridizira s komplementarnim lancem slijeda iz (i)(a), (i)(b), (i)(c) ili (i)(d).
15. Vektor, naznačen time što sadrži nukleinskokiselinski slijed u skladu s bilo kojim od patentnih zahtjeva 12 do 14.
16. Stanica, naznačena time što sadrži vektor u skladu s patentnim zahtjevom 15.
17. Stanica u skladu s patentnim zahtjevom 16, naznačena time što je navedena stanica bakterijska ili eukariotska.
18. Farmaceutski pripravak, naznačen time što sadrži ljudsko ili humanizirano protutijelo ili funkcionalni fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 11, te farmaceutski prihvatljiv nosač ili pomoćnu tvar.
19. Farmaceutski pripravak u skladu s patentnim zahtjevom 18, naznačen time što je namijenjen upotrebi u liječenju upalne bolesti.
20. Farmaceutski pripravak u skladu s patentnim zahtjevom 19, namijenjen upotrebi u skladu s patentnim zahtjevom 19, naznačen time što je navedena upalna bolest sa spiska na kojem su reumatoidni artritis, multipla skleroza, Crohnova bolest, psorijaza, astma i atopični dermatitis.
21. Farmaceutski pripravak u skladu s patentnim zahtjevom 19, namijenjen upotrebi u skladu s patentnim zahtjevom 19, naznačen time što je navedena upalna bolest reumatoidni artritis.
22. Ljudsko ili humanizirano protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačeno time što je namijenjeno upotrebi u liječenju upalne bolesti samo ili u kombinaciji s drugim sredstvima.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68200905P | 2005-05-18 | 2005-05-18 | |
| PCT/EP2006/004696 WO2006122797A2 (en) | 2005-05-18 | 2006-05-17 | Anti-gm-csf antibodies and uses therefor |
| EP06742970.4A EP1888643B1 (en) | 2005-05-18 | 2006-05-17 | Anti-gm-csf antibodies and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02059B true ME02059B (me) | 2015-05-20 |
Family
ID=37114333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-5A ME02059B (me) | 2005-05-18 | 2006-05-17 | Protutijela protiv gm-csf i njihova upotreba |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US7867495B2 (me) |
| EP (4) | EP2468773A3 (me) |
| JP (2) | JP5295759B2 (me) |
| KR (1) | KR101308087B1 (me) |
| CN (2) | CN103087190B (me) |
| AR (1) | AR053608A1 (me) |
| AU (1) | AU2006249062B2 (me) |
| BR (1) | BRPI0610796B8 (me) |
| CA (1) | CA2608498C (me) |
| CY (2) | CY1115920T1 (me) |
| DK (2) | DK3620171T3 (me) |
| ES (2) | ES2918209T3 (me) |
| HR (2) | HRP20150023T1 (me) |
| HU (1) | HUE058876T2 (me) |
| IL (1) | IL187375A (me) |
| LT (1) | LT3620171T (me) |
| ME (1) | ME02059B (me) |
| NO (1) | NO344992B1 (me) |
| NZ (1) | NZ564027A (me) |
| PL (2) | PL1888643T3 (me) |
| PT (2) | PT3620171T (me) |
| RS (2) | RS63382B1 (me) |
| RU (1) | RU2447085C2 (me) |
| SI (2) | SI1888643T1 (me) |
| TW (1) | TWI477512B (me) |
| WO (1) | WO2006122797A2 (me) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007012569A (es) | 2005-04-18 | 2007-12-06 | Micromet Ag | Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos. |
| ES2918209T3 (es) | 2005-05-18 | 2022-07-14 | Morphosys Ag | Anticuerpos anti-GM-CSF y usos a partir de los mismos |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| KR101395515B1 (ko) * | 2006-02-08 | 2014-05-14 | 모르포테크, 인크. | 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체 |
| US20080171038A1 (en) * | 2006-11-08 | 2008-07-17 | Kalobios Pharmaceuticals, Inc. | Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist |
| US20080206241A1 (en) | 2006-11-21 | 2008-08-28 | Kalobios Pharmaceuticals Inc. | Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist |
| US8398972B2 (en) | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| JP2010527939A (ja) * | 2007-05-23 | 2010-08-19 | シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド | 中和抗体 |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| WO2009062238A1 (en) * | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
| US8679502B2 (en) * | 2007-11-13 | 2014-03-25 | Evec Inc. | Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same |
| KR101559599B1 (ko) | 2007-11-26 | 2015-10-12 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 항-메소텔린 항체 및 이의 용도 |
| EP2088432A1 (en) * | 2008-02-11 | 2009-08-12 | MorphoSys AG | Methods for identification of an antibody or a target |
| KR101824512B1 (ko) * | 2008-04-28 | 2018-02-02 | 휴머니건, 아이엔씨. | 과립구-대식세포 콜로니 자극 인자에 대한 항체 |
| WO2009142738A2 (en) * | 2008-05-21 | 2009-11-26 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| KR20110044991A (ko) * | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＮＦ-α 길항제 다-표적 결합 단백질 |
| DK2376121T4 (da) * | 2008-12-22 | 2021-08-16 | Univ Melbourne | Slidgigtbehandling |
| EP3381471B1 (en) | 2008-12-22 | 2024-03-20 | The University of Melbourne | Pain treatment |
| CA2759506A1 (en) * | 2009-04-23 | 2010-10-28 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| US20120116059A1 (en) * | 2009-05-05 | 2012-05-10 | Morphosys Ag | Treatment For M Treatment For Multiple Sclerosis |
| BR112013033944A2 (pt) * | 2011-07-06 | 2017-12-19 | Morphosys Ag | combinação sinérgica |
| US9901079B2 (en) | 2011-08-18 | 2018-02-27 | New York University | Inhibition of oncogenic kras-induced GM-CSF production and function |
| WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| EP2843051B1 (en) | 2012-04-23 | 2018-06-06 | GeneFrontier Corporation | Anti-human cd69 antibody, and use thereof for medical purposes |
| KR102410763B1 (ko) * | 2012-08-17 | 2022-06-20 | 모르포시스 아게 | 복합체-특이적 항체 및 항체 단편 및 그의 용도 |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| CN104995210A (zh) * | 2012-09-20 | 2015-10-21 | 莫弗系统股份公司 | 类风湿关节炎的治疗 |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
| CN104937099B (zh) | 2012-11-09 | 2018-03-30 | 基因先端领域株式会社 | 用于治疗癌症的抗adam28抗体 |
| US20160024200A1 (en) * | 2013-03-14 | 2016-01-28 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
| RU2714919C2 (ru) | 2013-08-30 | 2020-02-21 | Такеда Гмбх | Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков |
| JP6202339B2 (ja) | 2013-12-19 | 2017-09-27 | 国立研究開発法人国立精神・神経医療研究センター | ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤 |
| US11173208B2 (en) | 2014-05-07 | 2021-11-16 | Takeda Gmbh | Liquid formulation comprising GM-CSF neutralizing compound |
| JP6490419B2 (ja) * | 2014-12-24 | 2019-03-27 | 学校法人関西医科大学 | 制御性ｔ細胞分化誘導剤 |
| GB201503139D0 (en) * | 2015-02-25 | 2015-04-08 | Univ Leicester | Diagnostic and therapeutic target |
| US10329358B2 (en) | 2015-03-06 | 2019-06-25 | Genefrontier Corporation | Anti-human membrane-type ADAM28 antibody |
| DK3328887T3 (da) * | 2016-09-19 | 2021-09-20 | I Mab Biopharma Hangzhou Co Ltd | Anti-GM-CSF antistoffer og anvendelser deraf |
| CN107840886B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| CN111757744A (zh) | 2017-10-02 | 2020-10-09 | 人源股份有限公司 | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| EP3623382A1 (en) | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
| US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| CN112805301B (zh) | 2018-10-15 | 2023-07-21 | 安立玺荣生医(香港)有限公司 | 粒细胞-巨噬细胞集落刺激因子的抗体及其用途 |
| US11078264B2 (en) | 2018-10-17 | 2021-08-03 | University Of Connecticut | Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth |
| US20220010007A1 (en) | 2018-11-09 | 2022-01-13 | Kiniksa Pharmaeuticals, Ltd. | Treatment for Giant Cell Arteritis |
| CA3127669A1 (en) * | 2019-01-07 | 2020-07-16 | Hunan Siweikang Therapeutics Co. Ltd | Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy |
| CN114599398A (zh) | 2019-06-03 | 2022-06-07 | 基尼克萨制药有限公司 | 用gm-csf拮抗剂治疗癌症 |
| WO2021188409A1 (en) | 2020-03-15 | 2021-09-23 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cytokine release syndrome with gm-csf antagonists |
| WO2021204649A1 (en) | 2020-04-06 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome |
| KR20230095983A (ko) | 2020-10-26 | 2023-06-29 | 키닉사 파마슈티컬스, 리미티드 | Gm-csf 길항제를 사용한 암의 치료 |
| NL2036015B1 (en) | 2023-10-12 | 2025-04-30 | Micronit Holding B V | A method of manufacturing a nozzle assembly, comprising weakening a wafer at at least two focal zones in the depth direction by focusing a laser beam |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994009149A1 (en) * | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| AUPP525198A0 (en) * | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
| CA2347973C (en) | 1999-07-20 | 2010-06-22 | Morphosys Ag | Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
| ATE444308T1 (de) * | 2002-02-13 | 2009-10-15 | Ludwig Inst Cancer Res | Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon |
| WO2004046330A2 (en) | 2002-11-15 | 2004-06-03 | Morphotek, Inc. | Methods of generating high-production of antibodies from hybridomas created by in vitro immunization |
| ATE435238T1 (de) | 2004-05-05 | 2009-07-15 | Micromet Ag | Herstellung eines einkettigen fv antikörperfragments |
| ES2918209T3 (es) * | 2005-05-18 | 2022-07-14 | Morphosys Ag | Anticuerpos anti-GM-CSF y usos a partir de los mismos |
-
2006
- 2006-05-17 ES ES19180152T patent/ES2918209T3/es not_active Expired - Lifetime
- 2006-05-17 ES ES06742970.4T patent/ES2527428T3/es not_active Expired - Lifetime
- 2006-05-17 AU AU2006249062A patent/AU2006249062B2/en not_active Ceased
- 2006-05-17 EP EP11187236A patent/EP2468773A3/en not_active Withdrawn
- 2006-05-17 PL PL06742970T patent/PL1888643T3/pl unknown
- 2006-05-17 SI SI200631880T patent/SI1888643T1/sl unknown
- 2006-05-17 BR BRPI0610796A patent/BRPI0610796B8/pt not_active IP Right Cessation
- 2006-05-17 EP EP06742970.4A patent/EP1888643B1/en not_active Expired - Lifetime
- 2006-05-17 EP EP16162171.9A patent/EP3150221A1/en not_active Withdrawn
- 2006-05-17 NZ NZ564027A patent/NZ564027A/en not_active IP Right Cessation
- 2006-05-17 CN CN201210510236.0A patent/CN103087190B/zh not_active Expired - Fee Related
- 2006-05-17 HR HRP20150023TT patent/HRP20150023T1/hr unknown
- 2006-05-17 CN CN2006800249817A patent/CN101218255B/zh not_active Expired - Fee Related
- 2006-05-17 WO PCT/EP2006/004696 patent/WO2006122797A2/en not_active Ceased
- 2006-05-17 RU RU2007147870/10A patent/RU2447085C2/ru active
- 2006-05-17 PT PT191801521T patent/PT3620171T/pt unknown
- 2006-05-17 EP EP19180152.1A patent/EP3620171B1/en not_active Expired - Lifetime
- 2006-05-17 HU HUE19180152A patent/HUE058876T2/hu unknown
- 2006-05-17 CA CA2608498A patent/CA2608498C/en not_active Expired - Lifetime
- 2006-05-17 RS RS20220609A patent/RS63382B1/sr unknown
- 2006-05-17 RS RS20150018A patent/RS53743B1/sr unknown
- 2006-05-17 KR KR1020077029189A patent/KR101308087B1/ko not_active Expired - Fee Related
- 2006-05-17 HR HRP20220755TT patent/HRP20220755T3/hr unknown
- 2006-05-17 US US11/914,599 patent/US7867495B2/en not_active Expired - Lifetime
- 2006-05-17 JP JP2008511635A patent/JP5295759B2/ja not_active Expired - Fee Related
- 2006-05-17 ME MEP-2015-5A patent/ME02059B/me unknown
- 2006-05-17 LT LTEP19180152.1T patent/LT3620171T/lt unknown
- 2006-05-17 DK DK19180152.1T patent/DK3620171T3/da active
- 2006-05-17 SI SI200632423T patent/SI3620171T1/sl unknown
- 2006-05-17 DK DK06742970.4T patent/DK1888643T3/en active
- 2006-05-17 PL PL19180152.1T patent/PL3620171T3/pl unknown
- 2006-05-17 PT PT67429704T patent/PT1888643E/pt unknown
- 2006-05-18 TW TW095117745A patent/TWI477512B/zh active
- 2006-05-18 AR ARP060102017A patent/AR053608A1/es unknown
-
2007
- 2007-11-14 IL IL187375A patent/IL187375A/en active IP Right Grant
- 2007-12-13 NO NO20076437A patent/NO344992B1/no unknown
-
2010
- 2010-09-16 US US12/923,363 patent/US9751939B2/en active Active
-
2013
- 2013-03-06 JP JP2013044573A patent/JP5769744B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-14 CY CY20151100030T patent/CY1115920T1/el unknown
-
2016
- 2016-12-21 US US15/386,152 patent/US10377820B2/en not_active Expired - Lifetime
-
2019
- 2019-06-17 US US16/442,779 patent/US11028165B2/en not_active Expired - Lifetime
-
2021
- 2021-05-07 US US17/314,198 patent/US20210347879A1/en not_active Abandoned
-
2022
- 2022-06-22 CY CY20221100427T patent/CY1125427T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150023T1 (hr) | Protutijela protiv gm-csf i njihova upotreba | |
| IL265434B2 (en) | Anti-cd27 antibodies | |
| RU2008137531A (ru) | Антитела к тимусному стромальному лимфопоэтину (tslp) и их применение | |
| RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
| Haurum | Recombinant polyclonal antibodies: the next generation of antibody therapeutics? | |
| JP2018121657A5 (me) | ||
| RU2013119957A (ru) | Человеческие антитела к онкостатину м и способы их применения | |
| HRP20211935T1 (hr) | Protutijela anti-alfa-sinuklein i njihove uporabe | |
| HRP20161141T1 (hr) | Anti-il-23 protutijela | |
| HRP20250482T1 (hr) | Protutijela koja se specifično vežu na ljudski il-15 i njihove uporabe | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| WO2009140348A4 (en) | Anti-il-6/il-6r antibodies and methods of use thereof | |
| JP2016135783A5 (me) | ||
| HRP20120175T1 (hr) | Antitijela s visokim afinitetom za humani il-6 receptor | |
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| JP2012116856A5 (me) | ||
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| SI2481753T1 (en) | Anti-IL-17 Antibodies | |
| RU2012151478A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| PE20080036A1 (es) | Anticuerpos humanos para la interleucina-13 (il13) | |
| HRP20160485T1 (hr) | Anti-mezotelinska protutijela i njihova uporaba | |
| JP2017518258A5 (me) | ||
| AR082916A1 (es) | Moleculas de union a 4-1bb | |
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin |